844 related articles for article (PubMed ID: 18618971)
1. Drug review "behind the curtain": a response to Professor Struve.
O'Reilly JT
Cornell Law Rev; 2008 Jul; 93(5):1075-90. PubMed ID: 18618971
[No Abstract] [Full Text] [Related]
2. The federal preemption debate in pharmaceutical labeling product liability actions.
Gross JM; Curry JA
Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
[No Abstract] [Full Text] [Related]
3. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
Vladeck DC
Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
[No Abstract] [Full Text] [Related]
4. The case for preemption of prescription drug failure-to-warn claims.
Kim CH
Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969
[No Abstract] [Full Text] [Related]
5. Bush tails follow-ons.
Fox J
Nat Biotechnol; 2008 Apr; 26(4):366. PubMed ID: 18392007
[No Abstract] [Full Text] [Related]
6. Drug safety reform at the FDA--pendulum swing or systematic improvement?
McClellan M
N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
[No Abstract] [Full Text] [Related]
7. Greater and lesser powers of tort reform: the primary jurisdiction doctrine and state-law claims concerning FDA-approved products.
Struve CT
Cornell Law Rev; 2008 Jul; 93(5):1039-74. PubMed ID: 18618970
[No Abstract] [Full Text] [Related]
8. Assessing supplement safety--the FDA's controversial proposal.
Cohen PA
N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
[No Abstract] [Full Text] [Related]
9. The FDA: is it protecting the public with one hand tied behind its back?
Shedlin RS
Law Med Health Care; 1992; 20(3):253-7. PubMed ID: 1434771
[No Abstract] [Full Text] [Related]
10. Regulators need to regulate. For health and safety issues, the nation needs watchdogs to be on guard.
May D
Mod Healthc; 2010 Mar; 40(9):16. PubMed ID: 20344831
[No Abstract] [Full Text] [Related]
11. Off-label or off-limits?
Ratner M; Gura T
Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
[No Abstract] [Full Text] [Related]
12. Pros and cons of off-label promotion investigations and prosecutions.
Loucks MK
Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
[No Abstract] [Full Text] [Related]
13. Good law from tragic facts--Congress, the FDA, and preemption.
Annas GJ
N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
[No Abstract] [Full Text] [Related]
14. The big gap at the FDA.
Stipp D
Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
[No Abstract] [Full Text] [Related]
15. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
Berry MD
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
[No Abstract] [Full Text] [Related]
16. Generic drug approval: a US perspective.
Nagori BP; Mathur V; Garg S
Curr Med Res Opin; 2011 Mar; 27(3):541-5. PubMed ID: 21219120
[TBL] [Abstract][Full Text] [Related]
17. PDUFA reauthorization--drug safety's golden moment of opportunity?
Hennessy S; Strom BL
N Engl J Med; 2007 Apr; 356(17):1703-4. PubMed ID: 17435082
[No Abstract] [Full Text] [Related]
18. US lawyers investigate trial that secured license for AstraZeneca's antiplatelet drug.
Cohen D
BMJ; 2013 Nov; 347():f6727. PubMed ID: 24212110
[No Abstract] [Full Text] [Related]
19. The Supreme Court, preemption, and malpractice liability.
Kesselheim AS; Studdert DM
N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
[No Abstract] [Full Text] [Related]
20. Paying for drug approvals--who's using whom?
Avorn J
N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
[No Abstract] [Full Text] [Related]
[Next] [New Search]